Drugs / EB-DuoNK-EGFR/HER2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07641023 | Mar 2026 → Mar 2027 expected | metastatic neoplasm, non-small cell lung carcinoma | Beijing Biotech | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EB-DuoNK-EGFR/HER2 | “Participants with tumors co-expressing EGFR and HER2/ERBB2 receive lymphodepletion followed by EB-DuoNK-EGFR/HER2 infusion at the assigned dose level.” NCT07641023 ↗ |
| Modality | Cell therapy | “Allogeneic cord-blood-derived NK cells engineered to express a dual-target CAR (tandem OR-gate) and IL-15 for enhanced persistence; includes an inducible safety switch ....” NCT07641023 ↗ |
| Route | Intravenous | “Infused intravenously on Day 1” NCT07641023 ↗ |